Sygnis SA

Equities

SYG

PLMODE000019

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
0.642 ^PLN	0.00%		+4.56%	-28.35%

05-15	Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-14	Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Mode S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 13, 2021 at 08:56 pm

MODE S.A. Announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was PLN 894,399.67 compared to PLN 507,568.11 a year ago. Operating income was PLN 87,551 compared to operating loss of PLN 180,482.85 a year ago. Net income was PLN 75,791.23 compared to net loss of PLN 190,793.82 a year ago.

Latest news about Sygnis SA

Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sygnis SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	19/03/23	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
Sygnis SA acquired majority stake in ZMorph sp. z o.o. from Warsaw Equity Group for PLN 3.64 Million.	28/07/22	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	20/03/22	CI
MODE S.A. will Change its Name to Sygnis SA	28/01/22	CI
MODE S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/11/21	CI
MODE S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/08/21	CI
Mode S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
An unknown buyer acquired 14.92% stake in MODE S.A. from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna.	17/06/18	CI

Chart Sygnis SA

Duration

Period

More charts

Company Profile

Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYGNIS SA	-28.35%	4.06M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research